Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBK2-ICG
- Development stage
- Phase 1
- Lead developer
- Case Western Reserve University
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
**SBK2-ICG** is an investigational, intravenously administered near-infrared fluorescence imaging agent for fluorescence-guided resection of glioma and other malignant brain tumors. It is a covalent conjugate of the 20-amino-acid SBK2 peptide and indocyanine green. The SBK2 peptide recognizes a tumor-associated biomarker derived from receptor-type tyrosine-protein phosphatase mu, enabling selective accumulation and near-infrared visualization of glioma tissue and tumor margins during surgery. SBK2-ICG is being evaluated in a Phase 1 safety and dose-finding study to support intraoperative delineation of tumor from normal brain tissue; it is not approved for this use.
02
Targets
PTPRM
Beyond the preview
Go deeper on SBK2-ICG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBK2-ICG.